Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function

https://doi.org/10.1016/j.amjopharm.2008.07.002Get rights and content

Abstract

Background: The National Kidney Foundation's practice guidelines for chronic kidney disease recommend using the Modification of Diet in Renal Disease (MDRD) equation for calculating the estimated glomerular filtration rate (GFR).

Objective: The purpose of this article was to compare the use of this estimated GFR with estimated creatinine clearance (CrCl) calculated using the Cockcroft-Gault equation (CGCrCl-Eq) in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Existing as well as new serum creatinine assay standards were used.

Methods: A PubMed literature search for all English-language articles published before November 2007 was conducted using the terms estimated glomerular filtration, GFR, modified diet in renal disease, MDRD, creatinine clearance, CrCl, drug dosing adjustment, renal impairment, human, and elderly. Mathematical comparisons of the age, race, and sex factors for these 2 equations (CGCrCl-Eq and MDRD) were performed, as well as a simulation of resulting values from these equations using various combinations of age, weight, and sex factors.

Results: None of the articles identified found that the use of the MDRD equation in the elderly was better than the CGCrCl-Eq for estimating renal drug elimination. Substantial mathematical differences are inherent in these 2 prediction equations that make any clinical comparison quite difficult. Implementation of new creatinine assay standards will further confuse the use of these 2 equations for estimating GFR and for dosage adjustments in elderly patients with renal insufficiency.

Conclusions: Although an MDRD equation may be useful for estimating GFR, the CGCrCl-Eq should still be used for drug dosage adjustments. The CGCrCl-Eq may require a slight “adjustment factor” to be applied using serum creatinine values measured by newly established assay procedures.

References (31)

  • G Remuzzi et al.

    Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition

    Ann Intern Med

    (2002)
  • GT Obrador et al.

    Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States

    J Am Soc Nephrol

    (1999)
  • DW Cockcroft et al.

    Prediction of creatinine clearance from serum creatinine

    Nephron

    (1976)
  • WJ Spruill et al.

    Estimating glomerular filtration rate with a modification of diet in renal disease equation: Implications for pharmacy [published correction appears in Am J Health Syst Pharm

    2007;64:916]. Am J Health Syst Pharm

    (2007)
  • GL Myers et al.

    for the National Kidney Disease Education Program

    Recommendations for improving serum creatinine measurement: A report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem

    (2006)
  • Cited by (63)

    • Drug Utilization Evaluation (DUE) of vancomycin: A cross-sectional study

      2022, Annals of Medicine and Surgery
      Citation Excerpt :

      In evaluation of vancomycin use in university-affiliated hospitals in Southern Khorasan Province (East Iran) based on HICPAC guidelines it was shown that only 10.6% of the patients showed inappropriate vancomycin use according to the HICPAC criteria [19]. Creatinine clearance is a relatively good estimate for renal dose adjustment; therefore, daily monitoring of serum creatinine and estimation of creatinine clearance, in addition to ensuring the appropriate dose of the drug, can be effective in preventing renal toxicity [20–22]. The difference between the renal toxicities of vancomycin may be due to the different criteria used to define renal toxicity, different study populations, and concomitant administration of nephrotoxic agents.

    • Drug dosing in cancer patients with decreased kidney function: A practical approach

      2021, Cancer Treatment Reviews
      Citation Excerpt :

      In general, there is an urgent need for additional studies investigating the validity of currently used estimates of kidney function in cancer patients and their applicability to traditional anticancer dosing. To date, most studies have compared the different formulas with each other in hypothetical simulations and not with actual drug clearance [90–97]. Future studies should ideally include therapeutic drug monitoring and clinical outcomes to establish the optimal dose for cancer patients with different degrees of kidney dysfunction.

    • Kidney function

      2019, Onco-Nephrology
    • Glomerular filtration rate estimation in people older than 85: Comparison between CKD-EPI, MDRD-IDMS and BIS1 equations

      2017, Nefrologia
      Citation Excerpt :

      There reports on CKD screening in population of individuals 60–80 y.o.7–9 using equations to calculate eGFR based on serum Cr. Information about the use of these equations in individuals >85 years of age is limited; the diet, weight and body surface10 are different in elderly and younger people. The study by Gómez-Pavón et al.9 in 70 patents >75 y.o. concludes that the values of eGFR obtained by the MDRD-IDMS are not the same as eGFR corrected by body surface or the estimated by the Cockcroft–Gault equation.9

    View all citing articles on Scopus
    View full text